stoxline Quote Chart Rank Option Currency Glossary
  
Longboard Pharmaceuticals, Inc. (LBPH)
59.98  0 (0%)    11-29 13:00
Open:
High: 59.98
Volume: 0
  
Pre. Close:
Low: 59.98
Market Cap: 2,342(M)
Technical analysis
2025-01-03 4:41:56 PM
Short term     
Mid term     
Targets 6-month :  70.05 1-year :  81.82
Resists First :  59.97 Second :  70.05
Pivot price 59.95
Supports First :  59.66 Second :  59.47
MAs MA(5) :  59.97 MA(20) :  59.91
MA(100) :  45.51 MA(250) :  31.1
MACD MACD :  0.9 Signal :  1.2
%K %D K(14,3) :  100 D(3) :  100
RSI RSI(14): 79.7
52-week High :  59.97 Low :  4.86
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ LBPH ] has closed below upper band by 39.3%. Bollinger Bands are 98% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 60.12 - 60.42 60.42 - 60.66
Low: 59.14 - 59.55 59.55 - 59.89
Close: 59.41 - 60.03 60.03 - 60.53
Company Description

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Headline News

Tue, 17 Dec 2024
Longboard Pharmaceuticals' SWOT analysis: bexicaserin potential drives stock outlook - Investing.com

Tue, 12 Nov 2024
Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs) - Business Wire

Thu, 07 Nov 2024
Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - Business Wire

Mon, 14 Oct 2024
Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline - Business Wire

Thu, 26 Sep 2024
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome - Business Wire

Fri, 20 Sep 2024
Longboard Stock Soars on FDA Designations for Epilepsy Drug - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 34 (M)
Shares Float 25 (M)
Held by Insiders 1.2 (%)
Held by Institutions 121.4 (%)
Shares Short 1,930 (K)
Shares Short P.Month 5,170 (K)
Stock Financials
EPS -2.25
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.05
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -30.8 %
Return on Equity (ttm) -46.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.54
Qtrly Earnings Growth 0 %
Operating Cash Flow -66 (M)
Levered Free Cash Flow -36 (M)
Stock Valuations
PE Ratio -26.66
PEG Ratio 0
Price to Book value 8.5
Price to Sales 0
Price to Cash Flow -31.34
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android